SCHEMBL5618652

SCHEMBL5618652

CNc1nccn2c(-c3ccc4[nH]c(C(=O)NCCCN5CCOCC5)cc4c3)cnc12

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 4/20 0.50
▸ ALDH1A1 P00352 3/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ MAPT P10636 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.47
▸ FLT3 P36888 1/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ RAD52 P43351 2/20 0.43
▸ HTT P42858 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ GLA P06280 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ TTK P33981 1/20 0.41
▸ DRD3 P35462 2/20 0.41
▸ DRD2 P14416 1/20 0.40
▸ DRD4 P21917 1/20 0.40
▸ ATM Q13315 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14573305 0.95 KDM4E (0.55) SYKALDH1A1KDM4EMAPTHSD17B10
SCHEMBL5405328 0.84 CD274 (0.55) ALDH1A1KDM4ESMN1; SMN2TTK
SCHEMBL5619095 0.83 FLT3 (0.49) SYKFLT3SMN1; SMN2
SCHEMBL14573304 0.81 NR4A1 (0.42) KDM4EFLT3KMT2AMEN1TTK
SCHEMBL4655966 0.80 SMN1; SMN2 (0.56) ALDH1A1MAPTFLT3SMN1; SMN2LMNA
SCHEMBL5412371 0.79 CD274 (0.62) TTK
SCHEMBL5618420 0.79 FLT3 (0.46) FLT3TTK
SCHEMBL5396618 0.79 SMN1; SMN2 (0.48) MAPTFLT3SMN1; SMN2DRD3DRD2
SCHEMBL5410621 0.77 TTK (0.57) ALDH1A1MAPTHTTSMN1; SMN2LMNA
SCHEMBL5618073 0.76 FLT3 (0.49) FLT3TTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US claimed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-7186832-B2 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN INC. (US) 2007-03-06 — — US disclosed
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors SUGEN, INC. 2005-01-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009832-A1 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors MAP3K8, MAP3K2, MAP3K5 SYK 700/4885ALDH1A1 2826/4885KDM4E 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback